Argent Biopharma (ASX:RGT) Cash-to-Debt : 13.88 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Argent Biopharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Argent Biopharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 13.88.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Argent Biopharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Argent Biopharma's Cash-to-Debt or its related term are showing as below:

ASX:RGT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.42 Med: 3.48 Max: No Debt
Current: 13.88

During the past 13 years, Argent Biopharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.42. And the median was 3.48.

ASX:RGT's Cash-to-Debt is ranked better than
78.87% of 1046 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs ASX:RGT: 13.88

Argent Biopharma Cash-to-Debt Historical Data

The historical data trend for Argent Biopharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Argent Biopharma Cash-to-Debt Chart

Argent Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

0.99

0.90

0.43

0.42

Argent Biopharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															3.91	0.43	0.46	0.42	13.88

Competitive Comparison of Argent Biopharma's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argent Biopharma's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's Cash-to-Debt falls into.

Argent Biopharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Argent Biopharma's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.24	/	(0.191	+	0.385)
	=	0.42

Argent Biopharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.482	/	(0.154	+	0.313)
	=	13.88

Argent Biopharma (ASX:RGT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Argent Biopharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Argent Biopharma (ASX:RGT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (ASX:RGT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

MGCLF:USA MXC:UK H5O:Germany

Address

295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008

Website

https://mgcpharma.co.uk

MGC Pharmaceuticals Ltd is a biopharma company with a Nature to Medicine strategy at the forefront of the emerging phytocannabinoid and plant-derived medicine markets. The company's mission is to build an innovative, global bio-pharma company providing standardized, affordable plant-derived medicines of the highest regulatory compliance for targeted global markets.